BMS-986465 / BMS - LARVOL DELTA

A Study to Evaluate the Safety, Tolerability, Drug Levels, Food, Formulation, and pH Effects on Relative Absorption of BMS-986465 and Its Active Derivative BMS-986464 in Healthy Participants (clinicaltrials.gov) - P1 | N=267 | Terminated | Sponsor: Bristol-Myers Squibb | N=132 ➔ 267 | Trial completion date: Mar 2025 ➔ Oct 2024 | Active, not recruiting ➔ Terminated | Trial primary completion date: Mar 2025 ➔ Oct 2024; Business objectives have changed

Enrollment change • Trial completion date • Trial primary completion date • Trial termination

A Study to Evaluate the Safety, Tolerability, Drug Levels, Food, Formulation, and pH Effects on Relative Absorption of BMS-986465 and Its Active Derivative BMS-986464 in Healthy Participants (clinicaltrials.gov) - P1 | N=132 | Active, not recruiting | Sponsor: Bristol-Myers Squibb | Recruiting ➔ Active, not recruiting

Enrollment closed

A Study to Evaluate the Safety, Tolerability, Drug Levels, Food, Formulation, and pH Effects on Relative Absorption of BMS-986465 and Its Active Derivative BMS-986464 in Healthy Participants (clinicaltrials.gov) - P1 | N=132 | Recruiting | Sponsor: Bristol-Myers Squibb | Not yet recruiting ➔ Recruiting

Enrollment open